EZH2 and cancer: As such, efforts to therapeutically target EZH2 have generally focused on inhibition of its methyltransferase activity8,12, although it remains undefined whether modulation of H3K27 trimethylation is the prominent mechanism whereby EZH2 promotes cancer.